These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9151734)

  • 1. Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction.
    Gomez CM; Maselli R; Gundeck JE; Chao M; Day JW; Tamamizu S; Lasalde JA; McNamee M; Wollmann RL
    J Neurosci; 1997 Jun; 17(11):4170-9. PubMed ID: 9151734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome.
    Gomez CM; Maselli RA; Groshong J; Zayas R; Wollmann RL; Cens T; Charnet P
    J Neurosci; 2002 Aug; 22(15):6447-57. PubMed ID: 12151524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desensitization of mutant acetylcholine receptors in transgenic mice reduces the amplitude of neuromuscular synaptic currents.
    Bhattacharyya BJ; Day JW; Gundeck JE; Leonard S; Wollmann RL; Gomez CM
    Synapse; 1997 Dec; 27(4):367-77. PubMed ID: 9372559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in different functional domains of the human muscle acetylcholine receptor alpha subunit in patients with the slow-channel congenital myasthenic syndrome.
    Croxen R; Newland C; Beeson D; Oosterhuis H; Chauplannaz G; Vincent A; Newsom-Davis J
    Hum Mol Genet; 1997 May; 6(5):767-74. PubMed ID: 9158151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic manipulation of AChR responses suggests multiple causes of weakness in slow-channel syndrome.
    Gomez CM; Maselli R; Williams JM; Bhattacharyya BB; Wollmann RL; Day JW
    Ann N Y Acad Sci; 1998 May; 841():167-80. PubMed ID: 9668235
    [No Abstract]   [Full Text] [Related]  

  • 6. A transgenic mouse model of the slow-channel syndrome.
    Gomez CM; Bhattacharyya BB; Charnet P; Day JW; Labarca C; Wollmann RL; Lambert EH
    Muscle Nerve; 1996 Jan; 19(1):79-87. PubMed ID: 8538674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms.
    Gomez CM; Maselli RA; Vohra BP; Navedo M; Stiles JR; Charnet P; Schott K; Rojas L; Keesey J; Verity A; Wollmann RW; Lasalde-Dominicci J
    Ann Neurol; 2002 Jan; 51(1):102-12. PubMed ID: 11782989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'.
    Slater CR; Fawcett PR; Walls TJ; Lyons PR; Bailey SJ; Beeson D; Young C; Gardner-Medwin D
    Brain; 2006 Aug; 129(Pt 8):2061-76. PubMed ID: 16870884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disorders affecting the acetylcholine receptor: myasthenia gravis and congenital myasthenia.
    Vincent A
    J Recept Res; 1987; 7(1-4):599-616. PubMed ID: 2442386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.
    Webster RG; Cossins J; Lashley D; Maxwell S; Liu WW; Wickens JR; Martinez-Martinez P; de Baets M; Beeson D
    Exp Neurol; 2013 Oct; 248():286-98. PubMed ID: 23797154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.
    Zhu H; Grajales-Reyes GE; Alicea-Vázquez V; Grajales-Reyes JG; Robinson K; Pytel P; Báez-Pagán CA; Lasalde-Dominicci JA; Gomez CM
    Exp Neurol; 2015 Aug; 270():88-94. PubMed ID: 25448156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes.
    Zhou M; Engel AG; Auerbach A
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10466-71. PubMed ID: 10468632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How myasthenia gravis alters the safety factor for neuromuscular transmission.
    Ruff RL; Lennon VA
    J Neuroimmunol; 2008 Sep; 201-202():13-20. PubMed ID: 18632162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utrophin abundance is reduced at neuromuscular junctions of patients with both inherited and acquired acetylcholine receptor deficiencies.
    Slater CR; Young C; Wood SJ; Bewick GS; Anderson LV; Baxter P; Fawcett PR; Roberts M; Jacobson L; Kuks J; Vincent A; Newsom-Davis J
    Brain; 1997 Sep; 120 ( Pt 9)():1513-31. PubMed ID: 9313636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mouse model for the slow-channel congenital myasthenic syndrome induced by the AChR εL221F mutation.
    Chevessier F; Peter C; Mersdorf U; Girard E; Krejci E; McArdle JJ; Witzemann V
    Neurobiol Dis; 2012 Mar; 45(3):851-61. PubMed ID: 22178625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newly recognized congenital myasthenic syndrome associated with high conductance and fast closure of the acetylcholine receptor channel.
    Engel AG; Uchitel OD; Walls TJ; Nagel A; Harper CM; Bodensteiner J
    Ann Neurol; 1993 Jul; 34(1):38-47. PubMed ID: 7685992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals.
    Zhu H; Bhattacharyya BJ; Lin H; Gomez CM
    J Neurosci; 2011 Oct; 31(43):15269-83. PubMed ID: 22031873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decremental response to high-frequency trains of acetylcholine pulses but unaltered fractional Ca2+ currents in a panel of "slow-channel syndrome" nicotinic receptor mutants.
    Elenes S; Decker M; Cymes GD; Grosman C
    J Gen Physiol; 2009 Feb; 133(2):151-69. PubMed ID: 19171769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor epsilon subunit gene: identification and functional characterization of six new mutations.
    Ohno K; Quiram PA; Milone M; Wang HL; Harper MC; Pruitt JN; Brengman JM; Pao L; Fischbeck KH; Crawford TO; Sine SM; Engel AG
    Hum Mol Genet; 1997 May; 6(5):753-66. PubMed ID: 9158150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
    Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
    Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.